Bionano Genomics (MEX:BNGO) Research & Development: MXN222.1 Mil (TTM As of Mar. 2026)


MEX:BNGO Bionano Genomics Inc MEX:BNGO
61 GF Score
Price MXN19.92
GF Value MXN27.78
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bionano Genomics Research & Development?

Bionano Genomics MEX:BNGO +0.61% 61 Research & Development is MXN222.1 Mil as of Mar. 2026. GuruFocus rates MEX:BNGO with a GF Score™ of 61/100 and a GF Value™ of MXN27.78 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bionano Genomics's Research & Development for the three months ended in Mar. 2026 was MXN56.6 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN222.1 Mil.

Bionano Genomics  (MEX:BNGO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bionano Genomics Research & Development Related Terms

Bionano Genomics Research & Development Historical Data

* Premium members only.

The historical data trend for Bionano Genomics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionano Genomics Research & Development Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 461.26 956.22 917.15 517.28 204.80

Bionano Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.49 55.19 52.17 58.14 56.61
MEX:BNGO
61GF Score
Bionano Genomics Inc MEX:BNGO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionano Genomics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN222.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN222.1 Mil mean?
Bionano Genomics (MEX:BNGO) has a Research & Development of MXN222.1 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Bionano Genomics and its competitors.
Is Bionano Genomics' Research & Development too high?
Bionano Genomics' current Research & Development is MXN222.1 Mil. Overall, Bionano Genomics has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Research & Development compare to UEEC and CUPR?
Bionano Genomics' Research & Development of MXN222.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bionano Genomics and its competitors. Bionano Genomics's current Research & Development is MXN222.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN27.78, compared to a current price of MXN19.92 — trading 28.3% below its estimated fair value. The current Research & Development is MXN222.1 Mil. Bionano Genomics' overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current Research & Development is MXN222.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?

Based on GuruFocus' analysis, Bionano Genomics stock appears to be undervalued. The current stock price of MXN19.92 is trading 28.3% below its estimated GF Value™ of MXN27.78. GuruFocus considers Bionano Genomics to be Modestly Undervalued.

Key valuation signals for MEX:BNGO:

  • Research & Development: MXN222.1 Mil
  • GF Value™: MXN27.78 vs. price of MXN19.92 (28.3% below fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bionano Genomics Business Description

Other Exchanges BNGO:USA
Address 9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
61GF Score

Get the complete analysis for MEX:BNGO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN19.92
Price
MXN27.78
GF Value